Development of quantitative RT-PCR assays for wild-type urokinase receptor (uPAR-wt) and its splice variant uPAR-del5

Radiology and Oncology

Volumn 38, Issue 2, 2004, Pages

  Farthmann, Juliane ^a   Holzscheiter, Leon ^a   Biermann, Julia ^a   Meye, Axel ^b   Luther, Thomas ^b   Kotzsch, Matthias ^b   Sweep, Fred ^c   Schmitt, Manfred ^a   Span, Paul ^c   Magdolen, Viktor ^a,d  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Neoplasms; Reverse transcriptase polymerase chain reaction; RNA splicing; RNA, messenger; Urinary plasminogen activator

Indexed keywords

COMPLEMENTARY DNA; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; RNA; UROKINASE; UROKINASE RECEPTOR;

ARTICLE; BRAIN CANCER; BREAST CANCER; CANCER INVASION; CELL STRAIN MCF 7; DNA SYNTHESIS; HOUSEKEEPING GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; METASTASIS; NUCLEOTIDE SEQUENCE; OVARY CANCER; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SPLICING; SOLID TUMOR; TUMOR CELL;

EID: 3142783465     PISSN: 13182099     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Magdolen U, Krol J, Sato S, Mueller MM, Krüger A, Sperl S, Schmitt M, Magdolen V. Natural inhibitors of tumor-associated proteases. Radiol Oncol 2002; 36: 131-43.
2. Sidenius N, Blasi F. The urokinase plasminogen activator system in cancer: recent advantages and implication for prognosis and therapy. Cancer Metast Rev 2003; 22: 205-22.
3. Blasi F, Carmeliet P. uPAR: a versatile signaling orchestrator. Nat Rev Mol Cell Biol 2002; 3: 932-43.
4. Harbeck N, Kates R, Gauger K, Willems A, Kiechle M, Magdolen V, Schmitt M. Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer. Thromb Haemost 2004; 91: 450-6.
5. Reuning U, Magdolen V, Wilhelm O, Fischer K, Lutz V, Graeff H, Schmitt M. Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis. Int J Oncol 1998; 13: 893-906.
6. Muehlenweg B, Sperl S, Magdolen V, Schmitt M, Harbeck N. Interference with the urokinase plasminogen activator system: a promising therapy concept for solid tumours. Expert Opin Biol Ther 2001; 1: 683-91.
7. Sperl S, Mueller MM, Wilhelm OG, Schmitt M, Magdolen V, Moroder L. The uPA/uPA receptor system as a target for tumor therapy. Drug News Perspect 2001; 14: 401-11.
8. Reuning U, Sperl S, Kopitz C, Kessler H, Krüger A, Schmitt M, Magdolen V. Urokinase-type plasminogen activator (uPA) and its receptor (uPAR): development of antagonists of uPA/uPAR interaction and their effects in vitro and in vivo. Curr Pharm Des 2003; 9: 1529-43.
9. Liu S, Aaronson H, Mitola DJ, Leppla SH, Bugge TH. Potent antitumor activity of a urokinase-activated engineered anthrax toxin. Proc Natl Acad Sci USA 2003; 100: 657-62.
10. Roldan AL, Cubellis MV, Masucci MT, Behrendt N, Lund LR, Danø K, Appella E, Blasi F. Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. EMBO J 1990; 9: 467-74.
11. Luther T, Kotzsch M, Meye A, Langerholc T, Füssel S, Olbricht N, Albrecht S, Ockert D, Muehlenweg B, Friedrich K, Grosser M, Schmitt M, Baretton G, Magdolen V. Identification of a novel urokinase receptor splice variant and its prognostic relevance in breast cancer. Thromb Haemost 2003; 89: 705-17.
12. Montuori N, Carriero M, Salzano S, Rossi G, Ragno P. The cleavage of the urokinase receptor regulates its multiple functions. J Biol Chem 2002; 277: 46932-9.
13. Beaufort N, Leduc D, Rousselle JC, Magdolen V, Luther T, Namane A, Chignard M, Pidard D. Proteolytic regulation of the urokinase receptor/CD87 on monocytic cells by neutrophil elastase and cathepsin G. J Immunol 2004; 172: 540-9.
14. Møller LB, Pollanen J, Rønne E, Pedersen N, Blasi F. N-linked glycosylation of the ligand-binding domain of the human urokinase receptor contributes to the affinity for its ligand. J Biol Chem 1993; 268: 11152-9.
15. Casey JR, Petranka JG, Kottra J, Fleenor DE, Rosse WF. The structure of the urokinase-type plasminogen activator receptor gene. Blood 1994; 84: 1151-6.
16. Magklara A, Scorilas A, Katsaros D, Massobrio M, Yousef GM, Fracchioli S, Danese S, Diamandis EP. The human KLK8 (neuropsin/ovasin) gene: identification of two novel splice variants and its prognostic value in ovarian cancer. Clin Cancer Res 2001; 7: 806-11.
17. Sweep CG, Geurts-Moespot J. EORTC external quality assurance program for ER and PgR measurements: trial 1998/1999. European Organisation for Research and Treatment of Cancer. Int J Biol Markers 2000; 15: 62-9.
18. Span PN, Tjan-Heijnen VC, Manders P, Beex LV, Sweep CG. Cyclin-E is a strong predictor of endocrine therapy failure in human breast cancer. Oncogene 2003; 22: 4898-904.
19. Köhler T, Lerche D, Meye A, Weisbrich C, Wagner O. Automated analysis of nucleic acids by quantitative PCR using coated ready-to-use reaction tubes. J Lab Med 1999; 23: 408-14.
20. Kotzsch M, Luther T, Harbeck N, Ockert D, Lutz V, Noack F, Grossmann D, Albrecht S, Kramer MD, Lossnitzer A, Grosser M, Schmitt M, Magdolen V. New ELISA for quantitation of human urokinase receptor (CD 87) in cancer. Int J Oncol 2000; 17: 827-34.